Antithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation
(WorldNews Health)

Contribution To Literature: Among patients with atrial fibrillation with recent ACS or PCI in the AUGUSTUS trial, adding apixaban to a P2Y12 inhibitor resulted in lower bleeding compared with VKA with a lower rate of death or rehospitalization. In both arms, addition of aspirin resulted in greater bleeding without any difference in efficacy. Description: The goal of the trial was to evaluate the role of dual therapy compared with triple therapy among patients with atrial fibrillation undergoing coronary revascularization. Study Design In a 2 x 2 factorial design, patients with atrial fibrillation undergoing coronary revascularization were randomized in a 1:1 fashion to either apixaban 5 mg...